All In Biotech

Drug Trial Radar · NCT04354545

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

75

Planned (sponsor's estimate)

Start

Apr 1, 2021

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
University of California, Los AngelesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Bausch & Lomb Incorporated
First posted
Apr 21, 2020

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate glaucoma patients' response to treatment with Xiidra, an FDA-approved drug for ocular surface discomfort, which will be prescribed as standard of care treatment.

Conditions

  • Glaucoma
  • Ocular Surface Disease

Interventions

  • Xiidra (Lifitegrast ophthalmic solution) 5%Drug

    FDA approved lifitegrast opthalmic solution eye drop

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline to week 12 in corneal fluorescein staining scoreTime frame: From baseline to Week 12
  2. Change from baseline to week 12 in eye dryness score (EDS)Time frame: From baseline to Week 12
  3. Change from baseline to week 12 in ocular surface disease index (OSDI) questionnaire scoreTime frame: From baseline to Week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Doheny Eye Center UCLA

    Fountain Valley, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.